About Rekvina Laboratories Limited
Data last updated: 13 July 2026
Rekvina Laboratories Limited is a public limited company based in Vadodara, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 01 November 1988, the company has been in operation for over 38 years.
Registered with ROC Ahmedabad under CIN L24231GJ1988PLC011458. Listed on BSE: 526075.
Capital: an authorised share capital of ₹3.5 Cr and a paid-up capital of ₹3.01 Cr. Formerly known as Rekvina Laboratories Private Limited. It is led by directors including Amit Mukesh Shah and Jay Chintan Patel.
Last AGM: 26 September 2025. Financial statements filed for year ended 31 March 2025. Office: Vadodara, Gujarat.
As per BSE-filed standalone financials for FY 2026, the company reported a revenue of ₹1.27 Cr. Total assets are valued at ₹1.19 Cr (up 3971.58% YoY).
The company is associated with 1 brand - Rekvina Laboratories. As per MCA filings, the company has open charges of ₹8.04 Cr on record.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website rekvinalaboratories.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered Address36 Sampatrao Colony, Next To Royal Hotel, Vadodara, Gujarat, India – 390007
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Rekvina Laboratories Limited
Rekvina Laboratories Limited has one previous CIN (Corporate Identification Number): U24231GJ1988PLC011458. The current CIN is L24231GJ1988PLC011458, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1988PLC011458 | Current |
| U24231GJ1988PLC011458 | Previous |
Associated Brands with Rekvina Laboratories Limited
Rekvina Laboratories Limited operates one associated brand: Rekvina Laboratories. These brands represent Rekvina Laboratories Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Medicines for gynecological disorders and surgical therapeutics are developed. | rekvinalaboratories.com |
Business Activity of Rekvina Laboratories Limited
Rekvina Laboratories Limited operates primarily in the manufacturing sector. The company has 1 registered business activity segment, reflecting its diverse operational portfolio.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Locked | Manufacturing | Locked | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Detailed business activity records for Rekvina Laboratories Limited
Activity codes and turnover contribution percentages require an active report plan.
- Activity group codes
- Detailed activity codes
- Turnover contribution
Verified entity values are shown only after access is granted.
Auditor Details of Rekvina Laboratories Limited
Rekvina Laboratories Limited is audited by M/s. Y M SHAH & CO. (ICAI peer reviewed, certificate valid till 2027-06-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s. Y M SHAH & CO. (ICAI peer reviewed, certificate valid till 2027-06-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Rekvina Laboratories Limited
Rekvina Laboratories Limited is currently managed by 5 directors, with 8 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Amit Mukesh Shah
Also directs:
Rekvina Laboratories Limited, Radiant Parenterals Limited, Rekvina Pharmaceuticals (India) Private Limited and 3 more
|
Managing Director | 01 Aug 2000 | 25 Years 11 Months | Current |
|
Jay Chintan Patel
Also directs:
Rekvina Laboratories Limited, Duchas Technologies Private Limited
|
Additional Director | 29 Jan 2026 | 0 Years 5 Months | Current |
|
Ila Rajendra Pathak
Also directs:
Rekvina Laboratories Limited, Radiant Parenterals Limited
|
Director | 02 Sep 2024 | 1 Years 10 Months | Current |
|
Prateek Jain
Also directs:
Rekvina Laboratories Limited, Jayam & Associates Llp
|
Additional Director | 06 Oct 2025 | 0 Years 9 Months | Current |
|
Surbhit Mukesh Shah
Also directs:
Rekvina Laboratories Limited, Radiant Parenterals Limited, Rekvina Pharmaceuticals (India) Private Limited and 2 more
|
Director | 27 Sep 2024 | 1 Years 9 Months | Current |
Financials of Rekvina Laboratories Limited FY 2026 filings available
Rekvina Laboratories Limited reported revenue of ₹1.27 Cr for FY 2026.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1.27 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Income | ₹0 | ₹0 | ₹0 | ₹38,000 | ₹0 | ₹0 | ₹15 Lakh | ₹1.06 Lakh |
| Total Income | ₹1.27 Cr | ₹0 | ₹0 | ₹38,000 | ₹0 | ₹0 | ₹15 Lakh | ₹1.06 Lakh |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹1.18 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹22.99 Lakh | ₹4.3 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹7.54 Lakh | ₹1.2 Lakh |
| Finance Costs | ₹0 | ₹0 | ₹0 | ₹4,000 | ₹34,000 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Expenses | ₹10.86 Lakh | ₹9.41 Lakh | ₹1.65 Lakh | ₹41,000 | ₹7.55 Lakh | ₹6.4 Lakh | ₹7.22 Lakh | ₹24.97 Lakh |
| Total Expenses | ₹1.52 Cr | ₹13.71 Lakh | ₹1.65 Lakh | ₹45,000 | ₹7.89 Lakh | ₹6.4 Lakh | ₹14.76 Lakh | ₹26.17 Lakh |
| Profit Before Exceptional Items & Tax | -₹25.47 Lakh | -₹13.71 Lakh | -₹1.65 Lakh | -₹7,000 | -₹7.89 Lakh | -₹6.4 Lakh | ₹24,000 | -₹25.11 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹25.47 Lakh | -₹13.71 Lakh | -₹1.65 Lakh | -₹7,000 | -₹7.89 Lakh | -₹6.4 Lakh | ₹24,000 | -₹25.11 Lakh |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹25.47 Lakh | -₹13.71 Lakh | -₹1.65 Lakh | -₹7,000 | -₹7.89 Lakh | -₹6.4 Lakh | ₹24,000 | -₹25.11 Lakh |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹25.47 Lakh | -₹13.71 Lakh | -₹1.65 Lakh | -₹7,000 | -₹7.89 Lakh | -₹6.4 Lakh | ₹24,000 | -₹25.11 Lakh |
| EBITDA (computed) | -₹25.47 Lakh | -₹13.71 Lakh | -₹1.65 Lakh | -₹3,000 | -₹7.55 Lakh | -₹6.4 Lakh | ₹24,000 | -₹25.11 Lakh |
| Basic EPS | ₹-0.42 | ₹-0.22 | ₹0.00 | ₹0.00 | ₹-0.13 | ₹0.00 | ₹0.00 | ₹-0.42 |
| Diluted EPS | ₹-0.42 | ₹-0.22 | ₹0.00 | ₹0.00 | ₹-0.13 | ₹0.00 | ₹0.00 | ₹0.00 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹1.19 Cr | ₹2.92 Lakh | ₹20.15 Lakh | ₹20.17 Lakh | ₹19.23 Lakh | ₹24.26 Lakh | ₹27.9 Lakh | ₹29.16 Lakh |
| Non-current Assets | ₹0 | ₹0 | ₹19.19 Lakh | ₹19.19 Lakh | ₹19.19 Lakh | ₹23.35 Lakh | ₹23.35 Lakh | ₹23.35 Lakh |
| Current Assets | ₹1.19 Cr | ₹2.92 Lakh | ₹96,000 | ₹98,000 | ₹4,000 | ₹91,000 | ₹4.55 Lakh | ₹5.81 Lakh |
| Property, Plant & Equipment | ₹0 | ₹0 | ₹14.61 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Trade Receivables | ₹59.65 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹40,000 | ₹96,000 |
| Cash & Equivalents | ₹1.53 Lakh | ₹2.51 Lakh | ₹96,000 | ₹98,000 | ₹4,000 | ₹21,000 | ₹1.1 Lakh | ₹2.36 Lakh |
| Equity (Net Worth) | -₹1.23 Cr | -₹33.84 Lakh | -₹32,000 | ₹1.32 Lakh | ₹1.4 Lakh | ₹9.3 Lakh | ₹15.7 Lakh | ₹15.46 Lakh |
| Equity Share Capital | ₹3.01 Cr | ₹3.01 Cr | ₹3.01 Cr | ₹3.01 Cr | ₹3.01 Cr | ₹3.01 Cr | ₹3.01 Cr | ₹3.01 Cr |
| Borrowings (Non-current) | ₹0 | ₹25.3 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹1.47 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹1.47 Cr | ₹25.3 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹2.42 Cr | ₹75,000 | ₹20.47 Lakh | ₹18.85 Lakh | ₹17.83 Lakh | ₹14.96 Lakh | ₹12.2 Lakh | ₹13.7 Lakh |
| Total Liabilities | ₹2.42 Cr | ₹36.76 Lakh | ₹20.47 Lakh | ₹18.85 Lakh | ₹17.83 Lakh | ₹14.96 Lakh | ₹12.2 Lakh | ₹13.7 Lakh |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | -₹59.43 Lakh | -₹19.18 Lakh | -₹3,000 | ₹95,000 | -₹4.33 Lakh |
| Investing Cash Flow | ₹0 | ₹0 | ₹0 | ₹0 | ₹4.16 Lakh |
| Financing Cash Flow | ₹58.46 Lakh | ₹20.74 Lakh | ₹0 | ₹0 | ₹0 |
| Capital Expenditure | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹59.43 Lakh | -₹19.18 Lakh | -₹3,000 | ₹95,000 | -₹4.33 Lakh |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹97,000 | ₹1.56 Lakh | -₹3,000 | ₹95,000 | -₹17,000 |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹72.36 Lakh | ₹34.56 Lakh | ₹19.62 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Income | ₹72.36 Lakh | ₹34.56 Lakh | ₹19.62 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹67.26 Lakh | ₹33.06 Lakh | ₹17.84 Lakh | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹6.41 Lakh | ₹10.11 Lakh | ₹3.77 Lakh | ₹2.7 Lakh | ₹3.35 Lakh | ₹0 | ₹0 | ₹0 |
| Finance Costs | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Depreciation & Amortisation | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Expenses | ₹4.74 Lakh | ₹3.78 Lakh | ₹1.5 Lakh | ₹84,000 | ₹93,000 | ₹2.43 Lakh | ₹6.65 Lakh | ₹26,000 |
| Total Expenses | ₹78.41 Lakh | ₹46.95 Lakh | ₹23.11 Lakh | ₹3.54 Lakh | ₹4.28 Lakh | ₹2.43 Lakh | ₹6.65 Lakh | ₹26,000 |
| Profit Before Exceptional Items & Tax | -₹6.05 Lakh | -₹12.39 Lakh | -₹3.49 Lakh | -₹3.54 Lakh | -₹4.28 Lakh | -₹2.43 Lakh | -₹6.65 Lakh | -₹26,000 |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | -₹6.05 Lakh | -₹12.39 Lakh | -₹3.49 Lakh | -₹3.54 Lakh | -₹4.28 Lakh | -₹2.43 Lakh | -₹6.65 Lakh | -₹26,000 |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | -₹6.05 Lakh | -₹12.39 Lakh | -₹3.49 Lakh | -₹3.54 Lakh | -₹4.28 Lakh | -₹2.43 Lakh | -₹6.65 Lakh | -₹26,000 |
| Other Comprehensive Income | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹6.05 Lakh | -₹12.39 Lakh | -₹3.49 Lakh | -₹3.54 Lakh | -₹4.28 Lakh | -₹2.43 Lakh | -₹6.65 Lakh | -₹26,000 |
| EBITDA (computed) | -₹6.05 Lakh | -₹12.39 Lakh | -₹3.49 Lakh | -₹3.54 Lakh | -₹4.28 Lakh | -₹2.43 Lakh | -₹6.65 Lakh | -₹26,000 |
| Basic EPS | ₹-0.10 | ₹-0.21 | ₹0.06 | ₹0.00 | ₹-0.07 | ₹0.04 | ₹0.11 | ₹0.00 |
| Diluted EPS | ₹-0.10 | ₹-0.21 | ₹0.06 | ₹0.00 | ₹-0.07 | ₹0.04 | ₹0.11 | ₹0.00 |
Shareholding Pattern of Rekvina Laboratories Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 41.30%, retail and other public shareholders hold 58.70% of Rekvina Laboratories Limited. The company had 2,475 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% |
| Public | 58.70% | 58.70% | 58.70% | 58.70% | 58.70% | 58.70% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 41.30% | 41.30% | 41.30% |
| Public | 58.70% | 58.70% | 58.70% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Charges & Borrowings of Rekvina Laboratories Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Dec 2203 | Bank of Baroda | ₹5 Lakh | Open |
| 13 Jul 1999 | Bank of Baroda | ₹1.9 Cr | Open |
| 24 Sep 1997 | Bank of Baroda | ₹1.9 Cr | Open |
| 13 Jul 1994 | Bank of Baroda | ₹1.9 Cr | Open |
| 10 Dec 1993 | Bank of Baroda | ₹53 Lakh | Open |
Total charge records: 10 View all charges
Employees and EPFO Compliance at Rekvina Laboratories Limited
View historical data on people associated with Rekvina Laboratories Limited, including employment history and EPFO contributions.
Employee and EPFO history for Rekvina Laboratories Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Rekvina Laboratories Limited
GST registrations and filing compliance for Rekvina Laboratories Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Rekvina Laboratories Limited
Credit ratings, litigation, and regulatory alerts for Rekvina Laboratories Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Rekvina Laboratories Limited
MSME payment history for Rekvina Laboratories Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Rekvina Laboratories Limited
Corporate group structure for Rekvina Laboratories Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Rekvina Laboratories Limited
MCA filings and documents for Rekvina Laboratories Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Rekvina Laboratories Limited
Frequently Asked Questions about Rekvina Laboratories Limited
Rekvina Laboratories Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 01 November 1988 (38+ years old) and is registered under CIN L24231GJ1988PLC011458. Listed on BSE: 526075.
Rekvina Laboratories Limited reported revenue of ₹1.27 Cr for FY 2026 based on standalone BSE filings.
The current directors of Rekvina Laboratories Limited are:
- Amit Mukesh Shah - Managing Director
- Jay Chintan Patel - Additional Director
- Ila Rajendra Pathak - Director
- Prateek Jain - Additional Director
- Surbhit Mukesh Shah - Director
The primary industry of Rekvina Laboratories Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Rekvina Laboratories Limited is listed on BSE with code 526075.
Rekvina Laboratories Limited can be reached at the registered office: 36 Sampatrao Colony, Next To Royal Hotel, Vadodara, Gujarat, India – 390007, or through the website rekvinalaboratories.com.